Serum Ferritin In CKD Patients Serum Ferritin | NCT05947552

Studies
Serum Ferritin In CKD Patients Serum Ferritin

NCT05947552

Sponsor

Assiut University

Status

Unknown status

Last Update Posted

Jul 17, 2023Actual

Enrollment

55Estimated

Phase

Not provided

Conditions

Chronic Kidney Diseases

Interventions

Serum ferritin

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jul 2023

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jul 8, 2023Estimated

Primary Completion Date

Jan 11, 2025Estimated

Completion Date

Jan 11, 2025Estimated

First Submitted Date

May 23, 2023

First Submission Date that Met QC Criteria

Jul 9, 2023

First Posted Date

Jul 17, 2023Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jul 9, 2023

Last Update Posted Date

Jul 17, 2023Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Yes

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Variability of serum ferritin in CKD patients and how these variables may affect the treatment decisions with iron supplements

Detailed Description

Serum ferritin has a wide range Variability in CKD patients this makes the use of serum ferritin as an indicator of iron deficiency is limited and mostly CKD is secondary to inflammation so serum ferritin as ferritin is an acute phase reactants so it will be very high in CKD patients ,

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

55Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Chronic kidney disease Patients		Chronic kidney Disease Patients stage 3 to stage 5	Drug: Serum ferritin

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Serum ferritin	Drug	Serum ferritin in CKD patients	Chronic kidney disease Patients

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
to assess the role of serum ferritin in CKD patients din in CKD patients and how these variability	affect treatment decisions with iron	Recurring

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

ALL CKD patients stage 3 to 5 not on dialysis

Exclusion Criteria:

inflammatory chronic diseases IDA Autoimmune disorders Liver diseases Malignancy Infections

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

50 Years

Standard Ages

Adult

Study Population

ALL CKD patients who are not dialysis Stage 3 to 5

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Reham Ma Osman, doctor	Contact	01065934817		rehamaskary1234@gmail.com
Alshaimaa Sy Hassan, Professor	Contact	01096883911		alshaimaamabarak@gmail.com

Overall Officials

Name	Affiliation	Role
Hawaid Ab Nafady, Professor	Assiut University	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Assiut university	Recruiting	Asyut			Egypt

IPD Sharing Statement Module

Plan to Share IPD

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D051436	Renal Insufficiency, Chronic

Ancestor Terms

ID	Term
D051437	Renal Insufficiency
D007674	Kidney Diseases
D014570	Urologic Diseases
D052776	Female Urogenital Diseases

Browse Leaves

Not provided

Browse Branches

Not provided